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The EPIC trial demonstrated the potent platelet IIbl1l1a inhibitor. c7E3 reduced
the incidence of acute complications in high risk angioplasty. The primary
endpoint was a composite of death. myocardial infarction (MI), repeat ur-
gent PTCA or CABG. and emergency stent or balloon pump insertion. Event
rates were recorded by the first occurrence of an endpoint, yet 30% of pts
experienced more than one endpoint. To further characterize the mecha-
nism of effect of potent platelet antagonism during angioplasty. we deter-
mined c7E3's efficacy according to the most serious endpoint reached. End-
points were ranked hierarchically according to degree of seriousness in the
order of death, MI, and urgent intervention. The three treatment groups were
placebo, bolus (B) or bolus plus infusion (B + I) of c7E3.
Results: There were no differences in death rates among the 3 treatment
groups, (although 2 pts who died in the B + I group never received the drug).
Reduction in MI in pts who survived (4.4% B + Ivs 7.9% placebo), accounted
for 78% of the 4.5% absolute decrease in the composite primary endpoint
by B + I (8.3% vs 12.8% placebo p = 0.003). In pts that survived and had
no MI, a reduction in urgent repeat intervention (2.2% vs 3.2% for placebo)
accounted for only 22% of the overall reduction of the primary endpoint by
B + I. Although urgent repeat intervention was less with B + I, the greatest
benefit was in pts who also had MI (1.4% vs 4.5% in placebo p < 0.001).
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Conclusions: Hierarchical endpoint analysis demonstrates that the mecha-
nism of benefit of c7E3 bolus plus infusion treatment in high risk angioplasty
was principally the reduction of MI, ratherthan a decrease in need for urgent
repeat intervention.
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While in recent years there has been concern with the cost of interventional
cardiology, technical improvements that may have impact to lower resource
utilization. Thus, the results of and indices of resource utilization of interven-
tional procedures in 17.263 patients from 1980 through 1993 were reviewed.
Previous studies have shown emergency surgery (CABG) and length of stay
(LOS) to be the strongest correlates of cost (r = 0.89). Results (mean or %.
MV ~ multivessel, EF = ejection fraction, New Dev = new devices, Ang
Suc = angiographic success, Q MI = Q wave myocardial infarction. BID =
number of balloons or devices, LOS in days):
reference segments. These findings have potentially important implications
for the clinical approach to intervention.
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1711-61 Declining Resource Utilization in Interventional
Cardiology
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Reference Pmin Pmax Parea CSAred
Segments (mm) (mm) Imm2) (%)
HCY <8 J,Lmol/L 0.18 076 438 32.3%
HCY >8 J,Lmol/L 0.27 1.04 6.98 40.3%
P value <0.0005 <0,0001 <0.0001 <0,0012
ministered as non-weight adjusted bolus doses to a therapeutic activated
clotting time (ACT): bleeding increased with maximal in-lab ACT and relative
heparin dose. To evaluate the safety and efficacy of weight-adjusted heparin
dosing during c7E3 administration (0.25 mglkg bolus, 10 mcglmin infusion
x 12 hrs). 103 pts undergoing coronary intervention were randomized to 1
of 2 regimens of heparin in a blinded fashion: 100 Ulkg bolus + additional
doses to achieve ACT> 300 sec (Standard Dose, n = 51), or 70 Ulkg bolus
without ACT adjustment (Low Dose, n = 52). ACT values immediately prior
to intervention (median and interquartile range) and bleeding complications
(unrelated to CABG) during the first 36 hrs (compared to 708 EPIC pts re-
ceiving same c7E3 dose). femoral hematoma >5 cm in size, and in-hospital
death or MI were:
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Low Plasma Homocysteine Levels Predict Reduced
Atheroma Burden in Patients Undergoing Coronary
Interventions: Evidence from Intravascular
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Thus, reduced weight-adjusted heparin dosing with c7E3 antiplatelet ther-
apy during coronary intervention in this pilot study did not increase ischemic
events, and at the same time appeared to decrease bleeding complications.
Weight-adjusted heparin strategies will be further tested in a large-scale, ran-
domized trial (EPILOG).
Objectives: Elevated plasma homocysteine (HCYI is an important risk factor
for premature coronary atherosclerosis. Intravascular ultrasound commonly
demonstrates extensive plaque burden at "normal" reference sites in inter-
ventional patients, averaging 38% area reduction. We performed this study
to determine if HCY levels predict which patients exhibit diffuse disease in-
volving reference segments.
Methods: We measured plasma homocysteine (J,LmoIlU in 62 patients
undergoing coronary interventions. Intravascular ultrasound was performed
with a 30 MHz, 3,5 F probe, examining both target lesions and reference
segments. A blinded core laboratory quantified four measures of atheroma
burden - maximum and minimum plaque thickness IPmin and Pmax ) respec-
tively, plaque cross-sectional area (Parea), and percentage cross-sectional
area reduction (CSAred)'
Results: Measures of atheroma extent and distribution at target lesions
were similar in both groups. However, at reference segments:
Strong statistical significance for a protective effect of a low homocys-
teine level persisted when controlling for age, gender, diabetes, hyperten-
sion, cholesterol and smoking in the two cohorts.
Conclusions: In interventional patients, low plasma homocysteine levels
independently predict the presence of focal atherosclerosis with sparing of
